

Price ₩17.00 52-week range ₩16.00 - ₩26.85 Market Cap. (₩'Bn) 533,740 1-month Avg. Vol 26,717,641 Curr. PB 0.65x

ZENITH:NL - Share Price Trend

28.0 26.0 24.0 22.0 20.0 18.0 16.0 14.0 12.0 10.0 Way-19 Analyst

Oluwasegun Akinwale
Oluwasegun.akinwale@arm.com.ng

Zenith Bank Plc. (Zenith.NL)

Initial View

In line, with few surprises in Q2

- Zenith released audited H1 19 result this afternoon, recording PBT and PAT growth of 4% and 9% (representing 50% and 48% of our FY 19 forecast) respectively. Specifically, on the Q2 19 numbers, EPS decline of 23% QoQ outperformed our expectation of 36% QoQ decline following higher than expected growth in NIR (+136% QoQ vs. estimate of 28% QoQ) emanating from higher trading income (T'bills and bonds), fee income (from electronic fees, credit related fees and account maintenance fees) and Other income which was dominated by N6.4 billion in FX revaluation gains. However, the higher NIR was neutered by 4.6x QoQ increase in credit loss provision to №11.6 billion (vs. estimate of №6.3 billion) and increased operating spend of №67 billion (+14% QoQ, vs. estimate of +16.9% QoQ).
- On the funding income, net interest income declined 35% QoQ with NIM contracting 276bps QoQ. While interest expense was broadly flat (-1.7% QoQ with WACF 7bps QoQ), interest income declined 25% QoQ (with yields on asset contracting 225bps QoQ), reflecting lower interest on treasury bills (-74% QoQ) and interest on loans (-3% QoQ).
- Our last communicated FVE of N33.61, translates to a STRONG BUY recommendation on our rating scale, key risks to our expectation is a more aggressive write-off during the year which could result in a much higher provisioning than expected. ZENITH trades at a FY 19E P/B of 0.65x, at a discount to GUARANTY of 1.28x.

Summary of Results and Forecast

N'million	H1 19	H1 18	YoY (pps)	Q1 19	Q2 19	QoQ
Gross Earnings	286,485	285,394	0.4%	169,195	155,136	9.1%
Net Interest Income	142,515	153,961	-7.4%	56,378	86,137	-34.5%
Non-Interest Revenue	109,730	88,595	23.9%	77,074	32,656	136.0%
Operating Expenses	(126,833)	(125,478)	1.1%	(67,429)	(59,404)	13.5%
Impairment	(13,735)	(9,720)	41.3%	(11,639)	(2,096)	455.3%
PBT	111,677	107,358	4.0%	54,384	57,293	-5.1%
PAT	88,882	81,737	8.7%	38,648	50,234	-23.1%
EPS	2.83	2.60	8.7%	1.23	1.60	-23.1%
N'million	H1 19	H1 18	YoY (pps)	Q1 19	Q2 19	
Loans	1,801,833	1,873,173	-3.8%	1,792,276	-0.5%	
Total Assets	5,898,596	5,256,460	12.2%	5,879,172	-0.3%	
Deposits	3,810,025	3,165,955	20.3%	3,571,370	-6.3%	
Total Liabilities	5,079,082	4,536,955	11.9%	5,098,284	0.4%	
Net Assets	819,514	719,505	13.9%	780,888	-4.7%	
BVPS	26.10	22.92	13.9%	24.87	-4.7%	
	H1 19	H1 18	change (pps)	Q1 19	Q2 19	change (pps)
Assets Yields	9.1%	10.6%	-1.5%	8.9%	6.7%	2.2%
WACF	$3.0^{\circ}/_{\circ}$	3.3%	-0.3%	3.1%	3.0%	0.1%
Net Interest Margin	6.1%	$7.2^{\circ}/_{\circ}$	-1.1%	7.8%	5.1%	$2.8^{\circ}/_{\circ}$
Cost-Income Ratio	50.3%	51.7%	-1.4%	50.0%	50.5%	-0.5%
Cost of Risk	1.5%	$1.0^{\circ}/_{\circ}$	0.5%	0.5%	2.6%	-2.1%
ROE	21.7%	22.7%	$-1.0^{\circ}/_{\circ}$	25.2%	19.3%	5.9%
CAR	25.0%	21.0%	$4.0^{\circ}/_{\circ}$	25.0%	25.0%	0.0%

Source: Company Financials, ARM Research

ARM ratings and recommendations

ARM now employs a two-tier rating system which is based on systemic importance of the security under review and the deviation of our target price for the stock from current market price. We characterize systemic importance as a function of a stock's ranking among the group of top 20 stocks by NSE market capitalization over a trailing 6-month period (minimum) to the review date. We adopt a 5-point rating system for this category of stocks and a 3-point rating system for stocks outside this group. The choice of top 20 stocks arises from the consideration that this group of stocks constitutes >75% of overall market capitalization and stocks outside this group are generally less liquid and individually account for <<1% of market capitalization. For stocks in both categories, the basis for ratings subject to target price deviation is outlined below:

TOP 20		NON-TOP 20	
Rating	Deviation	Rating	Deviation
STRONG BUY	>20%	BUY	>20%
OVERWEIGHT	10% — 20 %	NEUTRAL	5% — 20 %
NEUTRAL	0% — 10 %	SELL	< 5%
UNDERWEIGHT	-5% — 0%		
SELL	<-5%		

RECOMMENDATION	KEY
Rating	Recommendation
BUY	Accumulate security to a substantial extent constrained only by portfolio diversification considerations
OVERWEIGHT	Accumulate security to an extent moderated by cognizance of its benchmark weight
NEUTRAL	Maintain status quo for security with respect to current holding—i.e. keep if already holding and don't buy otherwise—subject to reasonable portfolio constraints
UNDERWEIGHT	Minimize exposure to security taking cognizance of its index weighting
SELL	Sell-off security completely from portfolio
	In certain circumstances, Asset & Resource Management ("ARM") Group policy and/or applicable law and regulations preclude certain
	types of communications, including an investment recommendation, during the course of ARM Securities' and/or ARM Group's
RESTRICTED	engagement in an investment banking transaction and in certain other circumstances.

Copyright © 2019 ARM Securities Limited ("ARMS").

All rights reserved. Unauthorized use, reproduction, distribution, or disclosure of this document is strictly prohibited.

This material has been issued by ARM Securities Limited, a member of the Asset and Resource Management ("ARM") Group, and a Company regulated by the Nigerian Securities & Exchange Commission. The analyst(s) primarily responsible for preparing this research report, in whole or in part, certifies that with respect to each security or issuer covered; all the views expressed accurately reflect his/her personal views about the subject securities and issuers and no part of his/her compensation was, is, or will be, directly or indirectly, related to the inclusion of specific recommendations or views in the report.

This research report is based on information from sources that ARMS and its analysts believe to be reliable. Neither ARMS nor any of its research analysts, nor any member of the ARM Group, gives any representation or warranty, express or implied, or undertaking of any kind or assumes responsibility or liability of any kind with respect to the accuracy or completeness of the information set out in this report or any third party's use (or the

results of such use) of such information. This report is provided solely for informational purposes and is not to be construed as providing advice, recommendations, or endorsements of any kind whatsoever. The investments and strategies discussed here may not be suitable for all investors; counsel of investment advisor should be obtained with regard to such investments and or strategies. This research report is not a replacement for advice from an accountant, lawyer, personal finance advisor or other category of investment advisor. The investments discussed in this report may oscillate in price or value. Opinions and information provided are made as of the date of the report issue and are subject to change without notice. This research report is not intended as an offer or solicitation for the purchase or sale of any financial instrument. Reference herein to any specific security or financial instrument does not necessarily constitute or imply its endorsement or recommendation by ARMS, its directors, officers, employees, or designated agents. Members of ARM may act as broker, advisor, or lender, or make a market in any investments or issuers referenced in this report. Further information on any of the securities discussed herein may be obtained upon request to ARMS. By accepting this document, you agree to be bound by the foregoing limitations.